An Audience With in 2023

Stuart Orkin, of Harvard Medical School and HHMI, discusses how the discovery of BCL11A paved the way for Vertex and CRISPR Therapeutics’ exa-cel therapy for haemoglobinopathies.

Jane Grogan, Biogen’s new head of research, talks about immunology, rare diseases and her longstanding interest in the cancer target TIGIT.

The Drugs for Neglected Diseases initiative’s Delali Attipoe, Director of the non-profit’s North America branch, discusses the rising risks of climate-sensitive diseases such as dengue.

ICER’s incoming President, Sarah Emond, discusses drug pricing, multimillion dollar gene therapies and innovation incentives.

Vividion CEO Aleksandra Rizo discusses emerging lessons from the firm’s use of fragment-based screening — including the potential for allosteric covalent drugs to drive different functional effects through a single binding site.

Incoming FogPharma CEO Mathai Mammen discusses the next frontier of cell-penetrating peptides, as the company advances a first candidate into the clinic to take on β-catenin.

Shiva Malek, head of oncology at Novartis Institutes for Biomedical Research, discusses her drug development ambitions — including drugging transcription factors, tackling drug resistance and curing KRAS-mutant cancer.

Joni Rutter, director of the National Center for Advancing Translational Sciences (NCATS), discusses the centre’s audacious goal to have 25% of diseases covered by the experimental drug pipeline by 2032.

Nobel laureate Bob Lefkowitz discusses the future of G-protein-coupled receptor (GPCR)-targeted drug discovery.

Aled Edwards celebrates 20 years of open science at the Structural Genomics Consortium — and keeps calling for more focus on understudied proteins.

Hans Clevers, head of Pharma Research & Early Development at Roche, discusses the role for organoids in drug discovery and development.